NKGen Biotech announces expansion of Phase 1/2a troculeucel trial

NKGen Biotech (NKGN) announced the activation of two additional clinical trial sites for its ongoing Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer’s disease. An activated clinical site refers to a site that has completed all necessary preparations, such as staff training and protocol set up, enabling the site to begin recruiting and enrolling patients. Site activation is key to initiating patient recruitment and ensuring the trial advances as planned. The newly activated sites, Ottawa Memory Clinic in Canada and AdventHealth Orlando in Florida, USA, are now open for patient enrollment, broadening access and accelerating recruitment for the trial. NKGen received clearance from Health Canada for its Clinical Trial Application, as disclosed in a prior press release, thus allowing the inclusion of Canadian patients in the Phase 1/2a trial. In Canada, the Ottawa Memory Clinic, a leader in Alzheimer’s disease research, will serve as a key site for Canadian patients. The AdventHealth Orlando site, led by Dr. Anita Fletcher, also previously disclosed in a prior press release, strengthens the trial’s presence on the U.S. East Coast. The Ottawa Memory Clinic site will be led by Richard Bergeron, M.D., Ph.D., a renowned neuroscientist with a deep background in neurodegenerative disease research, particularly Alzheimer’s disease